Screener
NewAmsterdam Pharma Company NAMS Net Income Loss
Net Income Loss at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| Foreign exchange gains/(losses) | (526) | 8,626 | (2,139) | 12,919 |
| Loss before tax | (64,135) | (17,364) | (112,576) | (56,891) |
| Income tax expense | — | — | — | — |
| Loss for the period | (64,135) | (17,364) | (112,576) | (56,891) |
| Other comprehensive income/(loss) | ||||
| Unrealized gain/(loss) on available-for-sale securities, net of tax | (360) | (107) | (932) | (140) |
| Total comprehensive loss for the period, net of tax | (64,495) | (17,471) | (113,508) | (57,031) |
| Net loss per ordinary share |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's net income loss?
- NewAmsterdam Pharma Company (NAMS) reported net income loss of -$64.14M in Q2 2026.
- How has NewAmsterdam Pharma Company's net income loss changed year-over-year?
- NewAmsterdam Pharma Company's net income loss decreased by 269.4% year-over-year, from -$17.36M to -$64.14M.
- What is the long-term trend for NewAmsterdam Pharma Company's net income loss?
- Over 3 years (2021 to 2025), NewAmsterdam Pharma Company's net income loss has grown at a 69.6% compound annual growth rate (CAGR), from -$41.79M to -$203.82M.
- What does net income loss mean?
- Net Income Loss as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude